Retour

Rani Therapeutics to Participate in August Investor Conferences

News Calendar of Events

SAN JOSE, Calif., Aug. 04, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that the Company will participate in three upcoming investor conferences in August 2023. These conferences include:

GlobeNewswire Inc. • 04/08/2023 à 22:05:00
Author • Rani Therapeutics, LLC
Rani Therapeutics Holdings, Inc. Class A Common Stock
Address: 2051 RINGWOOD AVENUE
Postal Code: 95131
City: SAN JOSE
State: CA
Phone Number: (408) 457-3700
Website: https://www.ranitherapeutics.com
Status: Active
Company Info

Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads up to 200 microlitre in liquid form with high bioavailability.

List Date2021-07-30
MarketStocks
LocalUS
Primary ExchangeXNAS
TypeCS
Currency NameUSD
CIK0001856725
Composite figiBBG011R6PZ44
Share Class figiBBG011R6PZZ0
Market Cap137,306,207 USD
SIC Code2834
SIC DescriptionPHARMACEUTICAL PREPARATIONS
Total Employees140
Share Class Shares Outstanding26300000
Weighted Shares Outstanding26303871
Round Lot100
Updated date2024-05-19
Stats
Last 5 days
17-05
16-05
15-05
14-05
13-05
Last
5.346
5.47
5.595
5.79
6.25
Variance
-3.2%
-2.23%
-3.2%
-7.36%
0.43%
Open
5.523
5.595
5.78
6.25
6.223
Highest
5.789
5.679
6.08
6.364
7.02
Lowest
5.73
5.61
6.08
6.325
7.02
History
PeriodVarhighestlowest
1 week
-14.09%
7.02
5.61
1 month
-22.59%
7.645
5.61
3 month
53.62%
3.552
3.231
6 month
167.3%
2.03
1.9
1 year
16.22%
4.71
1.82
3 year
-52.52%
12.2499
1.82
5 year
-52.52%
12.2499
1.82
10 year
-52.52%
12.2499
1.82
Stock Financials
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-10 2023-08-11 UNPUB UNPUB
Assets 96,446,000 83,507,000 UNPUB UNPUB
Current Assets 89,038,000 76,374,000 UNPUB UNPUB
Current Liabilities 5,150,000 5,735,000 UNPUB UNPUB
Equity 61,589,000 48,169,000 UNPUB UNPUB
Equity Attributable To Noncontrolling Interest 30,867,000 24,075,000 UNPUB UNPUB
Equity Attributable To Parent 30,722,000 24,094,000 UNPUB UNPUB
Liabilities 34,857,000 35,338,000 UNPUB UNPUB
Liabilities And Equity 96,446,000 83,507,000 UNPUB UNPUB
Noncurrent Assets 7,408,000 7,133,000 UNPUB UNPUB
Noncurrent Liabilities 29,707,000 29,603,000 UNPUB UNPUB
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-10 2023-08-11 UNPUB UNPUB
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow -8,023,000 -11,432,000 UNPUB UNPUB
Net Cash Flow, Continuing -8,023,000 -11,432,000 UNPUB UNPUB
Net Cash Flow From Financing Activities 8,000 80,000 UNPUB UNPUB
Net Cash Flow From Financing Activities, Continuing 8,000 80,000 UNPUB UNPUB
Net Cash Flow From Investing Activities 4,123,000 789,000 UNPUB UNPUB
Net Cash Flow From Investing Activities, Continuing 4,123,000 789,000 UNPUB UNPUB
Net Cash Flow From Operating Activities -12,154,000 -12,301,000 UNPUB UNPUB
Net Cash Flow From Operating Activities, Continuing -12,154,000 -12,301,000 UNPUB UNPUB
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-10 2023-08-11 UNPUB UNPUB
Comprehensive Income/Loss -16,706,000 -18,771,000 UNPUB UNPUB
Comprehensive Income/Loss Attributable To Noncontrolling Interest -8,397,000 -9,415,000 UNPUB UNPUB
Comprehensive Income/Loss Attributable To Parent -8,309,000 -9,356,000 UNPUB UNPUB
Other Comprehensive Income/Loss 126,000 -107,000 UNPUB UNPUB
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-10 2023-08-11 UNPUB UNPUB
Basic Earnings Per Share 0 0 UNPUB UNPUB
Benefits Costs and Expenses UNPUB UNPUB UNPUB UNPUB
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses UNPUB UNPUB UNPUB UNPUB
Diluted Earnings Per Share 0 0 UNPUB UNPUB
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -16,832,000 -18,664,000 UNPUB UNPUB
Income/Loss From Continuing Operations Before Tax -16,832,000 -18,664,000 UNPUB UNPUB
Income Tax Expense/Benefit UNPUB 0 UNPUB UNPUB
Interest Expense, Operating 1,207,000 1,266,000 UNPUB UNPUB
Net Income/Loss -16,832,000 -18,664,000 UNPUB UNPUB
Net Income/Loss Attributable To Noncontrolling Interest -8,460,000 -9,361,000 UNPUB UNPUB
Net Income/Loss Attributable To Parent -8,372,000 -9,303,000 UNPUB UNPUB
Net Income/Loss Available To Common Stockholders, Basic -8,372,000 -9,303,000 UNPUB UNPUB
Operating Expenses 16,516,000 18,294,000 UNPUB UNPUB
Operating Income/Loss -16,516,000 -18,294,000 UNPUB UNPUB
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 UNPUB UNPUB
Preferred Stock Dividends And Other Adjustments 0 0 UNPUB UNPUB
Revenues 0 0 UNPUB UNPUB
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-11 2022-08-10 2022-11-10 2023-03-22
Assets 115,309,000 104,344,000 108,202,000 108,027,000
Current Assets 109,260,000 97,993,000 100,720,000 100,924,000
Current Liabilities 4,156,000 5,349,000 7,186,000 4,815,000
Equity 110,644,000 98,654,000 86,607,000 74,004,000
Equity Attributable To Noncontrolling Interest 57,260,000 50,841,000 44,413,000 37,149,000
Equity Attributable To Parent 53,384,000 47,813,000 42,194,000 36,855,000
Liabilities 4,665,000 5,690,000 21,595,000 34,023,000
Liabilities And Equity 115,309,000 104,344,000 108,202,000 108,027,000
Noncurrent Assets 6,049,000 6,351,000 7,482,000 7,103,000
Noncurrent Liabilities 0 0 14,409,000 29,208,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-11 2022-08-10 2022-11-10 2023-03-22
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow 0 -20,272,000 -69,462,000 -89,946,000
Net Cash Flow, Continuing 0 -20,272,000 -69,462,000 -89,946,000
Net Cash Flow From Financing Activities 9,614,000 -9,565,000 14,082,000 29,005,000
Net Cash Flow From Financing Activities, Continuing 9,614,000 -9,565,000 14,082,000 29,005,000
Net Cash Flow From Investing Activities -254,000 -379,000 -71,346,000 -72,436,000
Net Cash Flow From Investing Activities, Continuing -254,000 -379,000 -71,346,000 -72,436,000
Net Cash Flow From Operating Activities -9,360,000 -10,328,000 -12,198,000 -46,515,000
Net Cash Flow From Operating Activities, Continuing -9,360,000 -10,328,000 -12,198,000 -46,515,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-11 2022-08-10 2022-11-10 2023-03-22
Comprehensive Income/Loss -13,828,000 -15,966,000 -16,326,000 -63,493,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 -8,314,000 -32,832,000
Comprehensive Income/Loss Attributable To Parent -13,828,000 -15,966,000 -8,012,000 -30,661,000
Other Comprehensive Income/Loss 0 0 -118,000 -149,000
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-11 2022-08-10 2022-11-10 2023-03-22
Basic Earnings Per Share 0 0 0 -1
Benefits Costs and Expenses UNPUB UNPUB UNPUB UNPUB
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses UNPUB UNPUB UNPUB UNPUB
Diluted Earnings Per Share 0 0 0 -1
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -13,828,000 -15,966,000 -16,208,000 -63,344,000
Income/Loss From Continuing Operations Before Tax -13,765,000 -15,812,000 -16,315,000 -63,274,000
Income Tax Expense/Benefit 63,000 154,000 -107,000 70,000
Interest Expense, Operating UNPUB UNPUB 352,000 1,071,000
Net Income/Loss -13,828,000 -15,966,000 -16,208,000 -63,344,000
Net Income/Loss Attributable To Noncontrolling Interest -7,605,000 -8,342,000 -8,253,000 -32,756,000
Net Income/Loss Attributable To Parent -6,223,000 -15,966,000 -7,955,000 -30,588,000
Net Income/Loss Available To Common Stockholders, Basic -13,828,000 -15,966,000 -7,955,000 -30,588,000
Operating Expenses 13,780,000 15,847,000 16,342,000 63,451,000
Operating Income/Loss -13,780,000 -15,847,000 -16,342,000 -63,451,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 0
Preferred Stock Dividends And Other Adjustments 0 0 0 0
Revenues 0 0 0 0
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB UNPUB 2021-11-16 2022-03-31
Assets UNPUB UNPUB 136,958,000 124,207,000
Current Assets UNPUB UNPUB 132,365,000 119,595,000
Current Liabilities UNPUB UNPUB 5,250,000 2,640,000
Equity UNPUB UNPUB 131,708,000 121,567,000
Equity Attributable To Noncontrolling Interest UNPUB UNPUB 80,342,000 74,156,000
Equity Attributable To Parent UNPUB UNPUB 51,366,000 47,411,000
Liabilities UNPUB UNPUB 5,250,000 2,640,000
Liabilities And Equity UNPUB UNPUB 136,958,000 124,207,000
Noncurrent Assets UNPUB UNPUB 4,593,000 4,612,000
Noncurrent Liabilities UNPUB UNPUB 0 0
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB UNPUB 2021-11-16 2022-03-31
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow UNPUB UNPUB 60,429,000 44,395,000
Net Cash Flow, Continuing UNPUB UNPUB 60,429,000 44,395,000
Net Cash Flow From Financing Activities UNPUB UNPUB 71,549,000 77,146,000
Net Cash Flow From Financing Activities, Continuing UNPUB UNPUB 71,549,000 77,146,000
Net Cash Flow From Investing Activities UNPUB UNPUB 0 -506,000
Net Cash Flow From Investing Activities, Continuing UNPUB UNPUB 0 -506,000
Net Cash Flow From Operating Activities UNPUB UNPUB -11,120,000 -32,245,000
Net Cash Flow From Operating Activities, Continuing UNPUB UNPUB -11,120,000 -32,245,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB UNPUB 2021-11-16 2022-03-31
Comprehensive Income/Loss UNPUB UNPUB -28,700,000 -53,088,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest UNPUB UNPUB 0 0
Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB -28,700,000 -53,088,000
Other Comprehensive Income/Loss UNPUB UNPUB 0 0
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB UNPUB 2021-11-16 2022-03-31
Basic Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Benefits Costs and Expenses UNPUB UNPUB 28,663,000 55,764,000
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses UNPUB UNPUB 28,663,000 55,764,000
Diluted Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax UNPUB UNPUB -28,700,000 -53,088,000
Income/Loss From Continuing Operations Before Tax UNPUB UNPUB -28,663,000 -53,047,000
Income Tax Expense/Benefit UNPUB UNPUB 37,000 41,000
Interest Expense, Operating UNPUB UNPUB 110,000 466,000
Net Income/Loss UNPUB UNPUB -28,700,000 -53,088,000
Net Income/Loss Attributable To Noncontrolling Interest UNPUB UNPUB -25,558,000 -44,757,000
Net Income/Loss Attributable To Parent UNPUB UNPUB -3,142,000 -8,331,000
Net Income/Loss Available To Common Stockholders, Basic UNPUB UNPUB -3,142,000 -8,331,000
Operating Expenses UNPUB UNPUB 27,781,000 -54,316,000
Operating Income/Loss UNPUB UNPUB -27,781,000 -51,599,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic UNPUB UNPUB 0 0
Preferred Stock Dividends And Other Adjustments UNPUB UNPUB 0 0
Revenues UNPUB UNPUB 0 2,717,000
Calendar
17 May 2024 (Time UTC) Actual Previous Consensus
★
15:30
United States
-17800.000
★
15:30
United States
-60000.000
★
15:30
United States
53700.000
★
15:30
United States
-135800.000
★★
15:30
United States
4400.000
★
15:30
United States
215400.000
★
15:30
United States
-31400.000
★
15:30
United States
62600.000
★
15:30
United States
1300.000
★
15:30
United States
-9700.000
★
15:30
United States
199600.000
★★
15:30
United States
★
15:30
United States
★
15:30
United States
★
15:30
United States
Options
Ticker
CFI
Contract Type
Exercise Style
Share Per Contract
Strike Price
Primary Exchange
Expiration Date
O:RANI240517P00007500 OPASPS Put American 100 7.5 BATO 2024-05-17
O:RANI240517P00005000 OPASPS Put American 100 5 BATO 2024-05-17
O:RANI240517P00002500 OPASPS Put American 100 2.5 BATO 2024-05-17
O:RANI240517C00007500 OCASPS Call American 100 7.5 BATO 2024-05-17
O:RANI240517C00005000 OCASPS Call American 100 5 BATO 2024-05-17
O:RANI240517C00002500 OCASPS Call American 100 2.5 BATO 2024-05-17
O:RANI240419P00007500 OPASPS Put American 100 7.5 BATO 2024-04-19
O:RANI240419P00005000 OPASPS Put American 100 5 BATO 2024-04-19
O:RANI240419P00002500 OPASPS Put American 100 2.5 BATO 2024-04-19
O:RANI240419C00007500 OCASPS Call American 100 7.5 BATO 2024-04-19
O:RANI240419C00005000 OCASPS Call American 100 5 BATO 2024-04-19
O:RANI240419C00002500 OCASPS Call American 100 2.5 BATO 2024-04-19
O:RANI240315P00007500 OPASPS Put American 100 7.5 BATO 2024-03-15
O:RANI240315P00005000 OPASPS Put American 100 5 BATO 2024-03-15
O:RANI240315P00002500 OPASPS Put American 100 2.5 BATO 2024-03-15
O:RANI240315C00007500 OCASPS Call American 100 7.5 BATO 2024-03-15
O:RANI240315C00005000 OCASPS Call American 100 5 BATO 2024-03-15
O:RANI240315C00002500 OCASPS Call American 100 2.5 BATO 2024-03-15
O:RANI240216P00007500 OPASPS Put American 100 7.5 BATO 2024-02-16
O:RANI240216P00005000 OPASPS Put American 100 5 BATO 2024-02-16
O:RANI240216P00002500 OPASPS Put American 100 2.5 BATO 2024-02-16
O:RANI240216C00007500 OCASPS Call American 100 7.5 BATO 2024-02-16
O:RANI240216C00005000 OCASPS Call American 100 5 BATO 2024-02-16
O:RANI240216C00002500 OCASPS Call American 100 2.5 BATO 2024-02-16
O:RANI240119P00007500 OPASPS Put American 100 7.5 BATO 2024-01-19
O:RANI240119P00005000 OPASPS Put American 100 5 BATO 2024-01-19
O:RANI240119P00002500 OPASPS Put American 100 2.5 BATO 2024-01-19
O:RANI240119C00010000 OCASPS Call American 100 10 BATO 2024-01-19
O:RANI240119C00007500 OCASPS Call American 100 7.5 BATO 2024-01-19
O:RANI240119C00005000 OCASPS Call American 100 5 BATO 2024-01-19
O:RANI240119C00002500 OCASPS Call American 100 2.5 BATO 2024-01-19
O:RANI240119P00010000 OPASPS Put American 100 10 BATO 2024-01-19
O:RANI231215P00007500 OPASPS Put American 100 7.5 BATO 2023-12-15
O:RANI231215P00005000 OPASPS Put American 100 5 BATO 2023-12-15
O:RANI231215P00002500 OPASPS Put American 100 2.5 BATO 2023-12-15
O:RANI231215C00007500 OCASPS Call American 100 7.5 BATO 2023-12-15
O:RANI231215C00005000 OCASPS Call American 100 5 BATO 2023-12-15
O:RANI231215C00002500 OCASPS Call American 100 2.5 BATO 2023-12-15
O:RANI231117C00005000 OCASPS Call American 100 5 BATO 2023-11-17
O:RANI231117C00002500 OCASPS Call American 100 2.5 BATO 2023-11-17
O:RANI231117P00007500 OPASPS Put American 100 7.5 BATO 2023-11-17
O:RANI231117P00005000 OPASPS Put American 100 5 BATO 2023-11-17
O:RANI231117P00002500 OPASPS Put American 100 2.5 BATO 2023-11-17
O:RANI231117C00007500 OCASPS Call American 100 7.5 BATO 2023-11-17
O:RANI231020P00010000 OPASPS Put American 100 10 BATO 2023-10-20
O:RANI231020P00007500 OPASPS Put American 100 7.5 BATO 2023-10-20
O:RANI231020P00005000 OPASPS Put American 100 5 BATO 2023-10-20
O:RANI231020P00002500 OPASPS Put American 100 2.5 BATO 2023-10-20
O:RANI231020C00010000 OCASPS Call American 100 10 BATO 2023-10-20
O:RANI231020C00007500 OCASPS Call American 100 7.5 BATO 2023-10-20
O:RANI231020C00005000 OCASPS Call American 100 5 BATO 2023-10-20
O:RANI231020C00002500 OCASPS Call American 100 2.5 BATO 2023-10-20
O:RANI230915P00007500 OPASPS Put American 100 7.5 BATO 2023-09-15
O:RANI230915P00005000 OPASPS Put American 100 5 BATO 2023-09-15
O:RANI230915P00002500 OPASPS Put American 100 2.5 BATO 2023-09-15
O:RANI230915C00007500 OCASPS Call American 100 7.5 BATO 2023-09-15
O:RANI230915C00005000 OCASPS Call American 100 5 BATO 2023-09-15
O:RANI230915C00002500 OCASPS Call American 100 2.5 BATO 2023-09-15
O:RANI230818P00010000 OPASPS Put American 100 10 BATO 2023-08-18
O:RANI230818P00007500 OPASPS Put American 100 7.5 BATO 2023-08-18
O:RANI230818P00005000 OPASPS Put American 100 5 BATO 2023-08-18
O:RANI230818P00002500 OPASPS Put American 100 2.5 BATO 2023-08-18
O:RANI230818C00010000 OCASPS Call American 100 10 BATO 2023-08-18
O:RANI230818C00007500 OCASPS Call American 100 7.5 BATO 2023-08-18
O:RANI230818C00005000 OCASPS Call American 100 5 BATO 2023-08-18
O:RANI230818C00002500 OCASPS Call American 100 2.5 BATO 2023-08-18
News Stream
Calendar Calendar of Events
Rani Therapeutics to Participate in May Investor Conferences
SAN JOSE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that the Company will participate in two upcoming investor conferences in May 2024. These conferences include:
GlobeNewswire Inc. • 5d ago
Calendar Calendar of Events
Rani Therapeutics to Present Clinical and Preclinical Data on Oral Delivery of an Ustekinumab Biosimilar via the RaniPill® Capsule at Digestive Disease Week 2024
SAN JOSE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it will present clinical and preclinical and data on the RaniPill® capsule, the company’s oral delivery platform, at Digestive Disease Week® (DDW) taking place both virtually and in-person on May 18-21, 2024 in Washington, DC.
GlobeNewswire Inc. • 1w ago
Stocks Earnings Releases and Operating Results
Rani Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Corporate Update
- Announced Positive Topline Results from Phase 1 Study of an Oral Anti-Interleukin 12/23 Antibody (RT-111) -
GlobeNewswire Inc. • 1mo ago
Calendar Calendar of Events
Rani Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results
SAN JOSE, Calif., March 15, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it plans to release financial results for the fourth quarter and full year ended December 31, 2023 and provide a business update on Wednesday, March 20 after the close of trading. Rani’s management team will host a conference call and webcast beginning at 4:30 p.m. ET.
GlobeNewswire Inc. • 2mo ago
News News
What Makes Rani Therapeutics Holdings, Inc. (RANI) a New Buy Stock
Rani Therapeutics Holdings, Inc. (RANI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks Investment Research • 5mo ago
Analyst Analyst Ratings
Analyst Ratings for Rani Therapeutics Hldgs
Rani Therapeutics Hldgs (NASDAQ:RANI) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 5 1 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 0 0 0 2M Ago 1 0 0 0 0 3M Ago 3 1 0 0 0 According to 6 analyst offering 12-month price targets in the last 3 months, Rani Therapeutics Hldgs has an average price target of $18.83 with a high of $20.00 and a low of $16.00. Below is a summary of how these 6 analysts rated Rani Therapeutics Hldgs over the past 3 ...Full story available on Benzinga.com
Benzinga • 6mo ago
Stocks Earnings Releases and Operating Results
Rani Therapeutics Reports Third Quarter 2023 Financial Results; Provides Corporate Update
- Cash runway extended into 2025 -
GlobeNewswire Inc. • 6mo ago
News Clinical Study
Rani Therapeutics Announces Successful Oral Delivery of Monoclonal Antibody via High-Capacity Pill in Preclinical Study
- RaniPill® HC achieved 4/4 successful drug delivery of orally administered Humira® (adalimumab) -
GlobeNewswire Inc. • 7mo ago
Calendar Calendar of Events
Rani Therapeutics to Present Abstract on RT-102 at the 2023 Annual Meeting of the American Society for Bone and Mineral Research
SAN JOSE, Calif., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it will present an abstract on RT-102 at the 2023 Annual Meeting of the American Society for Bone and Mineral Research (ASBMR) taking place on October 13-16, 2023 in Vancouver, British Columbia, Canada.
GlobeNewswire Inc. • 7mo ago
News Clinical Study
Rani Therapeutics Initiates Phase 1 Study of RT-111 (RaniPill® Containing Ustekinumab Biosimilar, CT-P43)
- Topline results from this study are expected in early Q1 2024
GlobeNewswire Inc. • 8mo ago
See All
Related
Latest

Contactez-nous dès aujourd'hui pour découvrir comment notre solution peut vous aider à tirer parti de la puissance des données.

CONTACTER UN EXPERT